Imunon Inc (IMNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imunon Inc (IMNN) has a cash flow conversion efficiency ratio of -952.715x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.99 Billion) by net assets ($4.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Imunon Inc stock valuation for the company's overall valuation and market capitalisation.
Imunon Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Imunon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Imunon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imunon Inc ranked by their cash flow conversion efficiency. Explore IMNN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
3.252x |
|
Skyline Investments Inc
TA:SKLN
|
-0.005x |
|
Canterbury Resources Ltd
AU:CBY
|
-0.060x |
|
Star Minerals Ltd
AU:SMS
|
-0.100x |
|
Evergold Corp
V:EVER
|
-0.033x |
|
Quantum Helium Limited
LSE:QHE
|
-0.096x |
|
UNITEDLABELS Aktiengesellschaft
F:ULC
|
0.048x |
|
GRAFT POLYMER UK LS -001
F:J4I
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Imunon Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Imunon Inc from 1996 to 2025. View today's stock price for Imunon Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.06 Million | $-13.90 Million | -1.968x | +55.70% |
| 2024-12-31 | $4.24 Million | $-18.85 Million | -4.442x | -212.65% |
| 2023-12-31 | $13.39 Million | $-19.02 Million | -1.421x | -80.42% |
| 2022-12-31 | $29.33 Million | $-23.10 Million | -0.788x | -170.85% |
| 2021-12-31 | $55.80 Million | $-16.22 Million | -0.291x | +65.35% |
| 2020-12-31 | $18.61 Million | $-15.62 Million | -0.839x | +39.69% |
| 2019-12-31 | $14.56 Million | $-20.26 Million | -1.392x | -312.24% |
| 2018-12-31 | $20.86 Million | $-7.04 Million | -0.338x | +45.84% |
| 2017-12-31 | $26.70 Million | $-16.64 Million | -0.623x | +77.19% |
| 2016-12-31 | $6.73 Million | $-18.38 Million | -2.733x | -167.43% |
| 2015-12-31 | $20.39 Million | $-20.83 Million | -1.022x | -57.08% |
| 2014-12-31 | $32.83 Million | $-21.35 Million | -0.651x | -115.28% |
| 2013-12-31 | $31.52 Million | $-9.53 Million | -0.302x | +83.68% |
| 2012-12-31 | $11.96 Million | $-22.14 Million | -1.851x | -113.22% |
| 2011-12-31 | $26.19 Million | $-22.74 Million | -0.868x | -129.72% |
| 2010-12-31 | $-4.58 Million | $-13.37 Million | 2.921x | +3251.52% |
| 2009-12-31 | $10.04 Million | $-930.33K | -0.093x | -180.16% |
| 2008-12-31 | $19.73 Million | $2.28 Million | 0.116x | +136.99% |
| 2007-12-31 | $30.65 Million | $-9.58 Million | -0.313x | -113.84% |
| 2006-12-31 | $-3.20 Million | $-7.23 Million | 2.260x | +195.98% |
| 2005-12-31 | $3.43 Million | $-8.06 Million | -2.354x | -102.16% |
| 2004-12-31 | $11.97 Million | $-13.94 Million | -1.165x | -72.38% |
| 2003-12-31 | $13.45 Million | $-9.09 Million | -0.676x | +88.76% |
| 2002-12-31 | $1.52 Million | $-9.11 Million | -6.008x | -157.70% |
| 2001-12-31 | $2.67 Million | $-6.22 Million | -2.332x | -426.22% |
| 2000-12-31 | $8.73 Million | $-3.87 Million | -0.443x | +80.74% |
| 1999-12-31 | $1.00 Million | $-2.30 Million | -2.300x | -301.53% |
| 1998-12-31 | $-1.85 Million | $-2.11 Million | 1.141x | +143.19% |
| 1997-12-31 | $-2.46 Million | $-1.15 Million | 0.469x | +316.77% |
| 1996-12-31 | $6.76 Million | $-1.46 Million | -0.216x | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more